CoolSculpting: How It Works, Cost, Results and Risks

CoolSculpting is a brand of fat-freezing device.

The clearance wording is literal: cold-assisted lipolysis — the breakdown of fat by cold.

The device is made by ZELTIQ, now part of Allergan Aesthetics (AbbVie).

It is a Class II medical device that FDA has cleared, not approved — cleared through the 510(k) pathway under the regulation "Contact Cooling System For Aesthetic Use" (21 CFR 878.4340, product code OOK).

FDA records show the first authorization was a De Novo grant (DEN090002) to ZELTIQ dated August 24, 2010, which created the product code; a 2017 review says that first clearance was for the flanks.

Later 510(k) clearances from 2012 to 2024 added areas and applicators.

The most recent clearance on file is K233732 for the CoolSculpting Elite System, dated September 12, 2024.

What the device is for is narrower than the marketing implies.

Allergan's consumer safety information states that CoolSculpting and CoolSculpting Elite are not treatments for weight loss.

The cleared use is reducing visible fat bulges in specific areas, within BMI limits written into the labeling.

Cryolipolysis cools a pocket of fat cold enough to injure the fat cells, and the body clears those injured cells slowly over the following months.

ASPS's description: the injured fat cells are gradually eliminated by the body over four to six months, and the fatty bulge decreases in size during that time.

The technical specs come from the device clearance itself.

The Elite system cools the treatment site to a target temperature as low as -11°C, with an accuracy of ±0.5°C, and it automatically stops if the temperature at the skin interface overshoots the target by more than 1°C when treating below 5°C.

One distinction worth making: localized cryolipolysis — CoolSculpting's category — is an FDA-cleared device.

Whole-body cryotherapy chambers are a different product: in a 2016 consumer update, FDA said no whole-body cryotherapy device had been cleared or approved for the medical claims spas make, weight loss included.

We did not research facial cryotherapy devices.

The cleared areas come from the K233732 clearance for CoolSculpting Elite, and they carry BMI limits written into the labeling.

For the body, the device is cleared for cold-assisted lipolysis of the following, in people with a BMI of 30 or less:

• upper arm
• bra fat
• back fat
• banana roll (under the buttocks)
• thigh
• abdomen
• flank ("love handles")

The same clearance also covers the submental area (under the chin) and the submandibular area (under the jawline) in people with a BMI up to 46.2 — and, for submental treatment, affecting the appearance of lax tissue.

Two scope notes.

First, that list is the cleared labeling; an area outside it is outside the cleared use for the device.

Second, fat bulges are not cellulite: the American Academy of Dermatology says cryolipolysis "currently cannot get rid of cellulite" and does not recommend it for that purpose.

Start with the honest answer: we could not find a published CoolSculpting price list to check a quote against — no Allergan or AbbVie list price per treatment cycle on any public manufacturer page, and no FDA document or professional-body source we checked gives a standard number of cycles per area.

The count is set by the provider's treatment plan.

The closest national figure comes from the American Society of Plastic Surgeons: an average cost of $1,157 for nonsurgical fat reduction, a category that includes cryolipolysis, Kybella, radiofrequency and laser lipolysis.

Its limits matter: it is the average fee reported by ASPS member surgeons, not a med spa price; ASPS says it is only part of the total price; and the page does not date its statistics (we read it in October 2026).

Because plans are built area by area and cycle by cycle, the written plan is the real price.

Ask which areas are included, how many cycles the plan assumes, and what a further cycle would cost if you wanted one.

For more on pricing, see what CoolSculpting costs.

Allergan's Allē loyalty program lists CoolSculpting as earning 400 to 500 points per visit (read October 20, 2026), and an Allē image caption describes 100 points as worth $10 — the program's own valuation; we did not review its redemption rules.

One cost no quote covers: Allergan says the rare enlargement side effect described below "will not resolve on its own" and may require surgery to correct.

CoolSculpting results are measured as a reduction in a fat layer, not as weight lost.

ASPS puts the average fat reduction at about 20 percent of the treated bulge, as the body clears the injured cells over four to six months.

For what that change can look like, see CoolSculpting before and after.

A 2015 systematic review pulled together 19 cryolipolysis studies (Ingargiola et al., Plastic and Reconstructive Surgery).

It found average fat-layer reductions of 14.67% to 28.5% measured with calipers and 10.3% to 25.5% measured with ultrasound.

The same review saw no significant effect on blood lipids or liver tests, and mainly mild, short-term side effects.

For a closer look at the evidence, see whether CoolSculpting works.

On timing, the American Academy of Dermatology says results can start as early as 3 weeks, and that most people see the full effect between 3 and 6 months after the last treatment.

The AAD lists 2 sessions as the typical count for cryolipolysis, though your provider's plan sets the real number.

During treatment, Allergan lists pulling, tugging, mild pinching, intense cold, tingling, stinging, aching and cramping, which lessen as the area becomes numb.

Afterward it lists temporary redness, swelling, blanching, bruising, firmness, stinging, tenderness, cramping, skin inflammation and aching.

Sensory changes — itching, skin sensitivity, tingling, numbness — can persist up to several weeks, and treating the chin or jawline can cause throat discomfort or a feeling of fullness in the back of the throat.

For more detail, see CoolSculpting side effects.

Allergan's marketing line is "little to no downtime" — on the same site whose safety information lists the effects above.

Plan around the lists, not the line.

Some people should not have it at all.

Allergan says people with cryoglobulinemia, cold agglutinin disease or paroxysmal cold hemoglobinuria should not be treated, and that patients should tell their doctor about pregnancy, recent surgery, a pre-existing hernia, or known sensitivities or allergies.

ASPS adds cold urticaria to the cold-related conditions, says people with loose skin or poor tone may not be suitable candidates, and says people who are pregnant or breastfeeding should not have nonsurgical fat reduction.

ASPS also lists surface irregularities, asymmetry and not getting the hoped-for result among the risks.

The serious risk to know by name is paradoxical adipose hyperplasia (PAH): the treated area visibly enlarges instead of shrinking.

Allergan describes this enlargement as a rare side effect: it may develop 2 to 5 months after treatment, will not resolve on its own and may need surgery to correct.

One device alternative is SculpSure, and it works in the opposite direction — heat.

SculpSure (Cynosure) uses a 1060 nm laser and was first cleared by FDA on May 15, 2015 (K150230) for non-invasive lipolysis of the flanks in people with a BMI of 30 or less, with later clearances adding areas.

Emsculpt-type devices add muscle to the picture.

The original Emsculpt-type clearances cover muscle toning and strengthening, with no fat-reduction indication; the fat-reduction indications belong to the radiofrequency-plus-HIFEM family marketed as Emsculpt NEO — cleared (K192224, December 5, 2019) for lipolysis and circumference reduction of the abdomen, originally for skin types I–III, with later versions adding the thighs and skin types I–VI.

Kybella is the injectable in this category, and it is a prescription drug, not a device: Kybella (deoxycholic acid) is FDA-approved only for moderate to severe fullness from submental fat in adults, and its label says it is not approved for fat outside the submental region and that such use is not recommended.

The label allows up to 6 single treatments at least 1 month apart.

In its pooled pivotal trials of 513 treated people, swelling or edema occurred in 87% (43% on placebo), bruising in 72% (70% on placebo), pain in 70%, numbness in 66%, redness in 27% and hardness in 23%.

Surgery is the remaining comparison, and the American Academy of Dermatology's summary of the whole non-invasive category is blunt: the results are subtle — its description is that pants fit a little looser — while liposuction gives more dramatic results.

Which of these fits a given person depends on the area, BMI against the cleared limits, and the change being sought — questions to take to a licensed provider at a consultation, along with a written plan and price for whichever option you discuss.

Once you have local options, the vetting is concrete.

Start with the legal frame: no federal law defines a "med spa," and whether one is regulated as a medical practice — and who may own it — is determined by each state's medical-practice, nursing and corporate-practice rules.

AmSpa's position is that med spas are medical practices.

State rules reach the device itself.

New Mexico's aesthetic nursing rule, for example, lists cryolipolysis among the procedures it regulates as "aesthetic healthcare procedures," alongside injectables, laser treatments and microneedling.

Whoever operates the device in your state, the rules are your state's — ask what license the person holds.

Expect a medical exam before a first treatment, in AmSpa's description of the "good faith exam": a physician, physician assistant or advanced practice nurse takes a medical history, performs an appropriate physical exam and creates the treatment order; an RN may assist but cannot generate the order.

AmSpa suggests repeating it when treatments change, when your health changes, or at least annually — its rule of thumb, not a statute.

Several of the screening questions above come straight from the device maker's own safety information and ASPS's candidate guidance — a consultation that never asks those is skipping the lists.

Get the plan — areas, cycles, total price, and who treats you — in writing before you pay anything.